Abstract
Corticotropin-releasing factor (CRF) is a neurohormone that plays a crucial role in integrating the body’s overall response to stress. It appears necessary and sufficient for the organism to mount functional, physiological and endocrine responses to stressors. CRF is released in response to various triggers such as chronic stress. The role of CRF and its involvement in these neurological disorders suggest that new drugs that can target the CRF function or bind to its receptors may represent a new development of neuropsychiatric medicines to treat various stress-related disorders including depression, anxiety and addictive disorders. Based on pharmacophore of the CRF1 receptor antagonists, a new series of thiazolo[4,5-d] pyrimidines were synthesized as Corticotropin-releasing factor (CRF) receptor modulators and the prepared compounds carry groups shown to produce optimum binding affinity to CRF receptors. Twenty two compounds were evaluated for their CRF1 receptor binding affinity in HEK 293 cell lines and two compounds 5o and 5s showed approximately 25% binding affinity to CRF1 receptors. Selected compounds (5c and 5f) were also evaluated for their effect on expression of genes associated with depression and anxiety disorders such as CRF1, CREB1, MAO-A, SERT, NPY, DatSLC6a3, and DBH and significant upregulation of CRF1 mRNA has been observed with compound 5c.
Keywords: Thiazolo[4, 5-d]pyrimidines, corticotropin releasing factor, antalarmin, anxiety, depression.
Medicinal Chemistry
Title:Synthesis of New Thiazolo[4,5-d]pyrimidines as Corticotropin Releasing Factor Modulators
Volume: 11 Issue: 1
Author(s): Bhimanna Kuppast, Katerina Spyridaki, Christophina Lynch, Yueshan Hu, George Liapakis, Gareth E. Davies and Hesham Fahmy
Affiliation:
Keywords: Thiazolo[4, 5-d]pyrimidines, corticotropin releasing factor, antalarmin, anxiety, depression.
Abstract: Corticotropin-releasing factor (CRF) is a neurohormone that plays a crucial role in integrating the body’s overall response to stress. It appears necessary and sufficient for the organism to mount functional, physiological and endocrine responses to stressors. CRF is released in response to various triggers such as chronic stress. The role of CRF and its involvement in these neurological disorders suggest that new drugs that can target the CRF function or bind to its receptors may represent a new development of neuropsychiatric medicines to treat various stress-related disorders including depression, anxiety and addictive disorders. Based on pharmacophore of the CRF1 receptor antagonists, a new series of thiazolo[4,5-d] pyrimidines were synthesized as Corticotropin-releasing factor (CRF) receptor modulators and the prepared compounds carry groups shown to produce optimum binding affinity to CRF receptors. Twenty two compounds were evaluated for their CRF1 receptor binding affinity in HEK 293 cell lines and two compounds 5o and 5s showed approximately 25% binding affinity to CRF1 receptors. Selected compounds (5c and 5f) were also evaluated for their effect on expression of genes associated with depression and anxiety disorders such as CRF1, CREB1, MAO-A, SERT, NPY, DatSLC6a3, and DBH and significant upregulation of CRF1 mRNA has been observed with compound 5c.
Export Options
About this article
Cite this article as:
Kuppast Bhimanna, Spyridaki Katerina, Lynch Christophina, Hu Yueshan, Liapakis George, Davies E. Gareth and Fahmy Hesham, Synthesis of New Thiazolo[4,5-d]pyrimidines as Corticotropin Releasing Factor Modulators, Medicinal Chemistry 2015; 11 (1) . https://dx.doi.org/10.2174/1573406410666140724115627
DOI https://dx.doi.org/10.2174/1573406410666140724115627 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Emerging Role of Endocrine Disruptors in Pathogenesis of Insulin Resistance: A Concept Implicating Nonalcoholic Fatty Liver Disease
Current Molecular Medicine Editorial [ Murine Atherosclerosis (Part III) Guest Editor: Godfrey S. Getz ]
Current Drug Targets Systemic DNA Damage Response and Metabolic Syndrome as a Premalignant State
Current Molecular Medicine Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews Harnessing the Potential of Long Non-coding RNAs to Manage Metabolic Diseases
Current Pharmaceutical Design Novel Nanostructured Polymeric Carriers to Enable Drug Delivery for Cardiovascular Diseases
Current Pharmaceutical Design Safety Aspects of Statins: Which Factors Create the Adverse Effects of Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings
Current Vascular Pharmacology Renin Angiotensin System Gene Polymorphisms in Response to Antihypertensive Drugs and Visit-To-Visit Blood Pressure Variability in Essential Hypertensive Patients
Current Pharmacogenomics and Personalized Medicine Mitochondrial Dysfunction, Oxidative Stress and Diabetic Cardiovascular Disorders
Cardiovascular & Hematological Disorders-Drug Targets Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease
Current Drug Targets Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Effects of Honey Against the Accumulation of Adipose Tissue and the Increased Blood Pressure on Carbohydrate-Induced Obesity in Rat
Letters in Drug Design & Discovery Cardiac Dysfunction in Rats with Dietary-Induced Insulin Resistance Associated with Pharmacologically-induced Dyslipidemia
Current Pharmaceutical Design Design, Synthesis, and Structure-Activity Relationship Study of Peroxisome Proliferator-Activated Receptor (PPAR) δ-Selective Ligands
Current Medicinal Chemistry Warming Up to New Possibilities with the Capsaicin Receptor TRPV1: mTOR, AMPK, and Erythropoietin
Current Neurovascular Research Smoking, Estradiol Metabolism and Hormone Replacement Therapy
Current Medicinal Chemistry - Cardiovascular & Hematological Agents